Newsfeeds - Spark Newswire

1 minute read

MacroGenics To Surge 138%? Plus This Analyst Sees $50 For Exact Sciences

Today, 2:22 PM

BMO Capital boosted the price target on MacroGenics, Inc. (NASDAQ: MGNX) from $5.7 to $16. BMO Capital analyst Etzer Darout upgraded the stock from Market Perform to Outperform. MacroGenics shares gained 3.5% to trade at $6.97 on Monday.

AIRS

1 minute read

HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Lowers Price Target to $50

By Benzinga Newsdesk

Today, 2:22 PM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and lowers the price target from $53 to $50.

RAPT

1 minute read

Piper Sandler Maintains Overweight on RAPT Therapeutics, Raises Price Target to $34

By Benzinga Newsdesk

Today, 2:22 PM

Piper Sandler analyst Edward Tenthoff maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $30 to $34.

RAPT

1 minute read

RAPT Therapeutics Q3 EPS $(0.63), Same YoY

By Benzinga Newsdesk

Today, 2:22 PM

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.63) per share. This is unchanged from the same period last year.

RAPT

1 minute read

Capital One Initiates Coverage On RAPT Therapeutics with Overweight Rating, Announces Price Target of $48

By Benzinga Newsdesk

Today, 2:22 PM

Capital One analyst Zegbeh Jallah initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces Price Target of $48.

RAPT

8 minute read

Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday

By Lisa Levin

Today, 2:22 PM

Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.

ACRX

6 minute read

Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 2:22 PM

Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year.

ACRX

1 minute read

Analyst Ratings

HC Wainwright & Co. Maintains Buy Rating for RAPT Therapeutics: Here’s What You Need To Know

By Benzinga Insights

Today, 2:22 PM

HC Wainwright & Co. has decided to maintain its Buy rating of RAPT Therapeutics (NASDAQ:RAPT) and raise its price target from $50.00 to $53.00. Shares of RAPT Therapeutics are trading up 14.98% over the last 24 hours, at $28.01 per share.

RAPT